New Agents for the Treatment of Type 2 Diabetes.

Adult Aged Aged, 80 and over Diabetes Mellitus, Type 2 / therapy Dipeptidyl-Peptidase IV Inhibitors / therapeutic use Female Glucagon-Like Peptide-1 Receptor / therapeutic use Humans Hypoglycemic Agents / therapeutic use Male Middle Aged Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
DPP-4 inhibitors Diabetes GLP-1 agonists New treatment SGLT-2 inhibitors

Journal

Critical care clinics
ISSN: 1557-8232
Titre abrégé: Crit Care Clin
Pays: United States
ID NLM: 8507720

Informations de publication

Date de publication:
Apr 2019
Historique:
entrez: 21 2 2019
pubmed: 21 2 2019
medline: 14 6 2019
Statut: ppublish

Résumé

The Renaissance of glucose-lowering therapies has arrived with multiple agents that lower blood glucose and demonstrate cardiovascular and renal benefits in people with type 2 diabetes. This article summarizes these new classes of therapies, including the sodium glucose co-transporter-2 inhibitors, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-4 inhibitors. Their cardiovascular safety profile, effects on glycemic, weight, and renal outcomes are discussed. As more options become available to treat type 2 diabetes, clinicians need to be aware of the advantages of each class of medications, beyond their glycemic lowering effects. The safety profiles are summarized in this article.

Identifiants

DOI: 10.1016/j.ccc.2018.11.007 PMID: 30784612
pubmed: 30784612
pii: S0749-0704(18)30775-9
doi: 10.1016/j.ccc.2018.11.007
pii:
doi:

Substances chimiques

Dipeptidyl-Peptidase IV Inhibitors 0
Glucagon-Like Peptide-1 Receptor 0
Hypoglycemic Agents 0
Sodium-Glucose Transporter 2 Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

315-328

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Renata Libianto (R)

Department of Medicine, The University of Melbourne, Austin Health, 300 Waterdale Road, Heidelberg West, Melbourne, Victoria 3081, Australia.

Elif I Ekinci (EI)

Department of Medicine, The University of Melbourne, Austin Health, 300 Waterdale Road, Heidelberg West, Melbourne, Victoria 3081, Australia; Department of Endocrinology, Austin Health, 300 Waterdale Road, Heidelberg West, Melbourne, Victoria 3081, Australia. Electronic address: elif.ekinci@unimelb.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › New Agents for the Treatment of Type 2 Diabetes.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › New Agents for the Treatment of Type 2 Diabetes.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › New Agents for the Treatment of Type 2 Diabetes.
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › New Agents for the Treatment of Type 2 Diabetes.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Inhibiteurs de la dipeptidyl-peptidase IV › New Agents for the Treatment of Type 2 Diabetes.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur hormone gastrointestinale › Récepteurs des peptides similaires au glucagon › Récepteur du peptide-1 similaire au glucagon › New Agents for the Treatment of Type 2 Diabetes.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › New Agents for the Treatment of Type 2 Diabetes.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › New Agents for the Treatment of Type 2 Diabetes.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › New Agents for the Treatment of Type 2 Diabetes.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Inhibiteurs du cotransporteur sodium-glucose de type 2 › New Agents for the Treatment of Type 2 Diabetes.